<div id="hybrid-search-3" class="widget search widget-search"><div class="widget-inside"><form method="get" class="search-form" id="search-form" action="https://rare-diseases.ca/"><div><input class="search-text" type="text" name="s" id="search-text" value="" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" /><input class="search-submit button" name="submit" type="submit" id="search-submit" value="Search" /></div></form><!-- .search-form --></div></div>
Rare Diseases
<div id="hybrid-nav-menu-3" class="widget nav-menu widget-nav-menu"><div class="widget-inside"></div></div>
<div class="breadcrumb breadcrumbs"><div class="breadcrumb-trail"> » <a href="https://rare-diseases.ca" title="" rel="home" class="trail-begin">Home</a> <span class="sep">»</span> <a href="https://rare-diseases.ca/people/" title="Our Team">Our Team</a> <span class="sep">»</span> <a href="https://rare-diseases.ca/people/investigator/" title="Investigators">Investigators</a> <span class="sep">»</span> Larry Lynd </div></div>

Larry Lynd, BSP, PhD

Project Principal Investigator

Dr. Larry Lynd received his BSP in 1986 from the University of Saskatchewan and his PhD in the Department of Health Care and Epidemiology at the University of British Columbia in 2002. He then completed a 2-year post-doctoral fellowship in health economics with Dr. Bernie O’Brien at McMaster University. He is a Professor in the Faculty of Pharmaceutical Sciences and is the Director of the Collaboration for Outcomes Research and Evaluation, CORE, at the University of British Columbia in Vancouver, Canada. He is a Scientist at the Centre for Clinical Epidemiology and Evaluation; Scientist at the Centre for Health Evaluation and Outcomes Sciences; Scholar at the Peter Wall Institute of Advanced Studies; and Associate of the School of Population and Public Health. He was a Michael Smith Foundation for Health Research Scholar and a Canadian Institutes of Health Research New Investigator.

Dr. Lynd has made significant service contributions, serving on a number of committees, including Chair of the Health Canada Special Advisory Committee on Non-prescription drugs; Special Advisory Committee to the Respiratory and Allergy Therapies Division of Health Canada; BC Ministry of Health Services Expensive Drugs for Rare Diseases Committee; and the BC PharmaNet Data Stewardship Committee.

His primary areas of scholarly interest are in the conduct of state of the art outcomes research and epidemiologic studies including cost-effectiveness analysis and therapeutic risk benefit analysis using state-of-the-art computer simulation modeling, measurement of health related quality of life and patient’s preferences, and pharmacoepidemiology. One of his primary research objectives is to be involved specifically in research that will ultimate translate into improved patient outcomes, or be integrated into the decision-making process.